Percutaneous iodine-125 seed implantation for carcinoma of the prostate.
This study was performed to assess the early results of treating stages T1-T3 adenocarcinoma prostate with either Iodine-125 (125I) implant alone (Group 1), for smaller more well differentiated cancers, or with low dose external beam radiation followed by a 125I boost (XRT + 125I) (Group 2) for larger less well differentiated tumours. Eighty-six patients were followed for between 11 and 60 months with a mean follow up of 26.1. All patients were followed by regular prostate specific antigen (PSA) evaluations, and digital rectal examinations (DRE). Eighty patients had a follow-up biopsy at 1 year. Prostate specific antigen progression-free survival (PSA-PFS) was determined and defined. Complications and potency were also assessed. Early results of 125I prostate seed implantation are very promising especially for selected cases of localized carcinoma.
Kaye
K W
KW
Department of Urology, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
Olson
D J
DJ
Payne
J T
JT
D000230:Adenocarcinoma / Q000150:complications / Q000473:pathology / Q000532:radiotherapy*; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology / Q000532:radiotherapy*; D017211:Treatment Failure
D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen